Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433199 | 0.83 | MAPT (0.39) | MAPTALDH1A1SLC9A3HTTL3MBTL1 | |
| SCHEMBL18950705 | 0.83 | MAPT (0.43) | MAPTALDH1A1SLC9A3HTTL3MBTL1 | |
| SCHEMBL300386 | 0.78 | HTR6 (0.44) | HTR6MAPTMMP2MMP9L3MBTL1 | |
| SCHEMBL6014544 | 0.76 | HTR6 (0.47) | HTR6MAPTMMP2MMP9HTT | |
| SCHEMBL6014405 | 0.74 | HTR6 (0.48) | HTR6MAPTMMP2MMP9 | |
| SCHEMBL6014355 | 0.74 | MMP9 (0.48) | HTR6MAPTMMP2MMP9ALDH1A1 | |
| SCHEMBL6014512 | 0.73 | HTR6 (0.44) | HTR6MAPTMMP2MMP9ALDH1A1 | |
| SCHEMBL6014510 | 0.73 | HTR6 (0.45) | HTR6MAPTMMP2MMP9ALDH1A1 | |
| SCHEMBL6014472 | 0.72 | MMP2 (0.47) | HTR6MAPTMMP2MMP9ALDH1A1 | |
| SCHEMBL6014557 | 0.72 | HTR6 (0.42) | HTR6MAPTMMP2MMP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028424-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-10604745-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190218592-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-10240184-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-03-21 | — | — | US | disclosed |
| EP-3179252-B1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | PROMEGA CORP (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10101332-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3179252-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | Promega Corporation (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2395078-B1 | Covalent tethering of functional groups to proteins | PROMEGA CORP (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION | 2008-01-31 | — | — | US | disclosed |
| EP-1782071-A2 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | PROMEGA CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| WO-2006093529-A2 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | PROMEGA CORPORATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060024808-A1 | Covalent tethering of functional groups to proteins and substrates therefor | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2006-02-02 | — | — | US | disclosed |
| US-20050272114-A1 | Substrates for covalent tethering to proteins | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2005-12-08 | — | — | US | disclosed |
| EP-1594962-A2 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072232-A9 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORP (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004072232-A2 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | HTR6 4312/4885MAPT 4367/4885MMP2 1497/4885 |
| US-20050272114-A1 | Substrates for covalent tethering to proteins | DDHD2, ABHD14B, AHCYL1 | HTR6 4379/4885MAPT 4307/4885MMP2 1797/4885 |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | WASF2, NOTUM, YIPF5 | HTR6 4312/4885MAPT 4367/4885MMP2 1497/4885 |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | HDHD5, DDT, DDAH1 | HTR6 2708/4885MAPT 4393/4885MMP2 344/4885 |
| US-20190218592-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | HTR6 4426/4885MAPT 4294/4885MMP2 1241/4885 |
| US-10604745-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | HDHD5, DDT, DDAH1 | HTR6 2708/4885MAPT 4393/4885MMP2 344/4885 |
| US-11028424-B2 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | HTR6 4426/4885MAPT 4294/4885MMP2 1241/4885 |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | HTR6 4426/4885MAPT 4294/4885MMP2 1241/4885 |
| US-10101332-B2 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | HTR6 4312/4885MAPT 4367/4885MMP2 1497/4885 |
| US-20060024808-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | HTR6 4312/4885MAPT 4367/4885MMP2 1497/4885 |
| US-10240184-B2 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | HTR6 4426/4885MAPT 4294/4885MMP2 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.